Sugi Predict

Sugi Predict / Targets / CSF3R

CSF3R

Granulocyte colony-stimulating factor receptor · Q99062 · CSF3R on Sugi Atlas →

67 patent compounds predicted against CSF3R, 24 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL18551002 SCHEMBL18551002 0.51 2/20
SCHEMBL2207505 SCHEMBL2207505 0.48 1/20
SCHEMBL2208586 SCHEMBL2208586 0.46 1/20
SCHEMBL29818702 SCHEMBL29818702 0.46 1/20
SCHEMBL11341527 SCHEMBL11341527 0.45 1/20
SCHEMBL11341529 SCHEMBL11341529 0.45 1/20
SCHEMBL28032739 SCHEMBL28032739 0.45 1/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL946939) 0.44 1/20
SCHEMBL4888126 SCHEMBL4888126 0.44 1/20
SCHEMBL611960 SCHEMBL611960 0.43 1/20
SCHEMBL26206374 SCHEMBL26206374 0.43 1/20
SCHEMBL27763796 SCHEMBL27763796 0.43 1/20
SCHEMBL4896415 SCHEMBL4896415 0.43 1/20
Hexanoate Hexanoate (SCHEMBL29036122) 0.43 1/20
SCHEMBL14018571 SCHEMBL14018571 0.42 1/20
SCHEMBL3964539 SCHEMBL3964539 0.42 1/20
SCHEMBL6179341 SCHEMBL6179341 0.42 1/20
SCHEMBL4282160 SCHEMBL4282160 0.42 1/20
SCHEMBL3882491 SCHEMBL3882491 0.41 1/20
SCHEMBL15805902 SCHEMBL15805902 0.41 1/20

Clinical trials — most relevant to CSF3R by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Bone Marrow Progenitor Cell Mobilization in Diabetes PHASE4COMPLETED
Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality PHASE3COMPLETED
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions PHASE3RECRUITING
Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT) PHASE3ACTIVE_NOT_RECRUITING
Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome. PHASE3ACTIVE_NOT_RECRUITING
Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia PHASE2COMPLETED
The Effectiveness of GM-CSF in HIV-Positive Patients Who Are Also Receiving Anti-HIV Therapy PHASE2COMPLETED
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms PHASE1/PHASE2RECRUITING
Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis PHASE2COMPLETED
GM-CSF as Adjuvant Therapy of Melanoma PHASE2COMPLETED
CSL324 in COVID-19 PHASE2WITHDRAWN
Stem Cell Mobilization With Pegfilgrastim in Lymphoma and Myeloma PHASE2COMPLETED
GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer PHASE2WITHDRAWN
Niraparib + Dostarlimab + RT in Pancreatic Cancer PHASE2COMPLETED
Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer PHASE2ACTIVE_NOT_RECRUITING
A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Safety and Efficacy of Tag-7 Gene-modified Vaccine in Locally Advanced or Metastatic Malignant Melanoma or Kidney Cancer PHASE1/PHASE2COMPLETED
Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas PHASE2COMPLETED
BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC) PHASE2COMPLETED
GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma PHASE2COMPLETED
Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
Reirradiation and Niraparib in Patients With Recurrent Glioblastoma PHASE1WITHDRAWN
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors PHASE1ACTIVE_NOT_RECRUITING
Gene Therapy for Chronic Granulomatous Diseases - Long-term Follow-up PHASE1COMPLETED
Dose Escalation and Cohort Expansion Study of YS-ON-001 in Patients With Advanced Solid Tumors PHASE1COMPLETED
Ifosfamide and Topotecan in Treating Patients With Refractory Solid Tumors PHASE1COMPLETED
Clinical Trial Protocol for the Combined Use of VAG in the Treatment of ND-AML nanRECRUITING
Assessment of Salivary GM-CSF, MIP, and IL-1β Levels in Subjects With Varying Periodontal Conditions nanRECRUITING
Intrauterine Infusion of GCSF and Reproductive Outcomes in Infertile Women with History of RIF nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CSF3R binder may also engage these)

ProteinNameSimilarity
P40223 — 0.994 P40223 →
MPL Thrombopoietin receptor 0.994 landscape →
Q08351 — 0.992 Q08351 →
P22273 — 0.991 P22273 →
Q6UWB1 — 0.989 Q6UWB1 →
P42701 — 0.987 P42701 →
P22272 — 0.986 P22272 →
O70394 — 0.984 O70394 →
Q8MJS1 — 0.984 Q8MJS1 →
Q9BEG2 — 0.984 Q9BEG2 →
Q60837 — 0.982 Q60837 →
P14753 — 0.980 P14753 →
O70540 — 0.979 O70540 →
P26954 — 0.979 P26954 →
P0DP72 — 0.979 P0DP72 →
Q9HC73 — 0.978 Q9HC73 →
P34902 — 0.978 P34902 →
P31785 — 0.978 P31785 →
Q61826 — 0.978 Q61826 →
P32927 — 0.977 P32927 →
Q99665 — 0.977 Q99665 →
Q95118 — 0.977 Q95118 →
Q07303 — 0.976 Q07303 →
A0A140LHF2 — 0.976 A0A140LHF2 →
Q96AP7 — 0.976 Q96AP7 →
EPOR Erythropoietin receptor 0.976 landscape →
Q7L513 — 0.976 Q7L513 →
Q9MYZ9 — 0.976 Q9MYZ9 →
Q80ZE3 — 0.976 Q80ZE3 →
Q8K4C2 — 0.976 Q8K4C2 →